- Lestaurtinib
-
- $0.00 / 1kg
-
2026-01-27
- CAS:111358-88-4
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 20tons
- Lestaurtinib
-
- $499.00 / 1mg
-
2025-12-22
- CAS:111358-88-4
- Min. Order:
- Purity: 99.17%
- Supply Ability: 10g
- Lestaurtinib USP/EP/BP
-
- $1.10 / 1g
-
2025-11-18
- CAS:111358-88-4
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | Lestaurtinib Basic information |
| Product Name: | Lestaurtinib | | Synonyms: | Lestaurtinib
(KT-5555;CS-1165;lestaurtinib;(9S-(9α,10β,12α))-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxyMethyl)-9-Methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one;SPM-924;CEP-701 hydrate;KT-5555 hydrate;Lestaurtinib hydrate | | CAS: | 111358-88-4 | | MF: | C26H21N3O4 | | MW: | 439.47 | | EINECS: | | | Product Categories: | Inhibitor;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 111358-88-4.mol |  |
| | Lestaurtinib Chemical Properties |
| Melting point | 215-220°C | | Boiling point | 723.0±60.0 °C(Predicted) | | density | 1.70±0.1 g/cm3(Predicted) | | storage temp. | Desiccate at -20°C | | solubility | DMSO: >10mg/mL | | pka | 13.37±0.40(Predicted) | | form | white powder | | color | White or off-white | | Stability: | Photosensitive | | InChIKey | LPOQWFBZBJTLEO-GMEYHWBASA-N | | SMILES | O.C[C@]12O[C@H](C[C@]1(O)CO)n3c4ccccc4c5c6C(=O)NCc6c7c8ccccc8n2c7c35 |
| WGK Germany | 3 | | HS Code | 2934999090 | | Storage Class | 11 - Combustible Solids |
| | Lestaurtinib Usage And Synthesis |
| Description | Lestaurtinib (111358-88-4) is a potent and selective FLT3 inhibitor (IC50= 2 nM).1,2?Inhibits RET and RET phosphorylation in medullary thyroid carcinoma cells.3?Suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.4?Potent Trk inhibitor.5?Cell permeable. | | Chemical Properties | Lestaurtinib is Off-White Solid | | Uses | Lestaurtinib is used for the treatment of pancreatic cancer and acute myelogenous leukaemia (AML) | | Uses | It is used for the treatment of pancreatic cancer and acute myelogenous leukaemia (AML). | | Uses | CEP-701 hydrate has been used as a tyrosine kinase inhibitor:
- to study its effects on early growth response protein (EGR) genes and nerve growth factor (NGF) stimulation in human epithelial cells
- as a supplement in reservoir solution for co-crystallization studies with human receptor-interacting?protein kinase?4 (RIPK4)
- as an FMS-like tyrosine kinase 3 (FLT3) inhibitor-gold nanoparticle conjugate to study its effects on acute myeloid leukemia
| | Definition | ChEBI: LSM-1231 is an indolocarbazole. | | Biological Activity | Potent JAK2, FLT3 and TrkA inhibitor (IC 50 values are 0.9, 3 and < 25 nM respectively) that prevents STAT5 phosphorylation (IC 50 = 20 - 30 nM). Exhibits antiproliferative activity in vitro (IC 50 = 30 - 100 nM in HEL92.1.7 cells) and is effective against myeloproliferative disorders in vivo . | | Biochem/physiol Actions | CEP-701 hydrate, also known as Lestaurtinib, can repress Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5) signaling by the specific inhibition of JAK2. | | storage | -20°C (desiccate) | | References | [1] MARK LEVIS Donald S. Novel FLT3 tyrosine kinase inhibitors.[J]. Expert opinion on investigational drugs, 2003, 12 12: 1951-1962. DOI:10.1517/13543784.12.12.1951
[2] PEILI CHEN. FLT3/ITD mutation signaling includes suppression of SHP-1.[J]. The Journal of Biological Chemistry, 2005, 280 7: 5361-5369. DOI:10.1074/jbc.m411974200
[3] CHRISTOPHER J STROCK. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth.[J]. Cancer research, 2003: 5559-5563.
[4] ELIZABETH O HEXNER. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.[J]. Blood, 2008: 5663-5671. DOI:10.1182/blood-2007-04-083402
[5] B A RUGGERI. Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models.[J]. Current medicinal chemistry, 1999, 6 9: 845-857. |
| | Lestaurtinib Preparation Products And Raw materials |
|